CTO-PCI Technology for Heart Health in Egypt
The article from the Egypt Healthcare Authority (EHA) discusses the successful implementation and benefits of using CTO-PCI (Chronic Total Occlusion Percutaneous Coronary Intervention) technology to treat chronic coronary artery occlusion in Egypt. Here are some key points to consider:
- Success of Procedures: The EHA reported the successful treatment of three elderly patients (all over 60 years old) using CTO-PCI technology with micro-catheters and specialised wires at the International Medical Complex in Luxor. The procedures achieved a 100% success rate.
- Cost and Universal Health Coverage: The cost of CTO-PCI procedures outside the universal health coverage system exceeds 500,000 Egyptian pounds. However, under the universal health insurance system, patients contribute no more than 400 EGP.
- Medical Team and Expertise: The procedures were conducted by a highly skilled team of medical consultants, including top professors, cardiologists, and specialised nursing and technical staff. Key team members included Dr. Tarek Rashid, Head of the Scientific Committee for Cardiology, and Dr. Zein El-Abidin Abdel-Latif, Head of the Cardiology and Catheterization Department.
- Commitment to Innovation: The EHA emphasised its commitment to innovation and continuous development, adopting the latest global medical advances and introducing cutting-edge technologies across all medical specialties, particularly in cardiology.
- Patient Benefits: The patients treated were suffering from angina and severe pain due to coronary artery occlusion. The use of CTO-PCI technology significantly improved their quality of life.
- Healthcare Model: The EHA aims to provide a modern healthcare model in Egypt by ensuring access to the latest global medical advancements and maintaining a team of expert consultants.
This initiative reflects the Authority‘s dedication to providing innovative medical technologies and achieving high-quality care for patients under the universal health insurance system.
Recent Posts
Advancements in Factor XIa Inhibition Stroke Prevention Through Asundexian
The European Medicines Agency has accepted Bayer’s marketing authorization application for asundexian, marking a major advance in Factor XIa Inhibition Stroke prevention. This oral agent selectively interrupts a key step in the coagulation cascade to reduce recurrent ischemic stroke risk in adult...
Transforming Clinical Skill Assessment with Intelligent Evaluation Systems
Clinical skill assessment has long been hampered by subjective judgments and variability among examiners. A novel unified intelligent framework replaces these manual observations with contrastive learning to deliver objective, trace...
Advancing Medical AI through Federated Generative Learning
Federated Generative Learning is emerging as a practical breakthrough for multi-center medical image analysis, simultaneously tackling communication overhead, data scarcity, and institutional heterogeneity. The framework trains a shared prompt generator that produces individualized visual prompts...